FY2025 · ended Dec 31, 2025 · Revenue $9.22M, +0.4% YoY · Filed Apr 1, 2026
Aspira Women’s Health Inc. (AWHL) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $9.2 million and a net loss of $12.8 million. Free cash flow was -$7.0 million. As of Jun 30, 2026 it held $477,000 in cash and investments and $3.1 million in total debt.
Revenue (TTM)
$8.55M
-8.0% vs year-ago TTM
Net income (TTM)
$-10.01M
-5.8% vs year-ago TTM
Operating cash flow (TTM)
$-4.56M
+48.0% vs year-ago TTM
Free cash flow (TTM)
$-4.69M
EPS (TTM)
$-0.24
+43.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
43.50M
+46.1% vs prior year
Net cash
$-2.63M
as of Jun 30, 2026
Operating margin
-80.8%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- AWHL (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 926617
- Former names
- VERMILLION, INC. (until Jun 10, 2020); CIPHERGEN BIOSYSTEMS INC (until Aug 17, 2007)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $9.2M | $9.2M | $87.0M | $8.2M | $6.8M |
| Operating income | -$7.9M | -$16.3M | -$18.9M | -$31.1M | -$32.6M |
| Net income | -$12.8M | -$13.1M | -$16.7M | -$29.9M | -$31.7M |
| Diluted EPS | -$0.37 | -$0.93 | -$1.81 | -$3.85 | -$4.27 |
| Operating cash flow | -$7.0M | -$12.1M | -$15.9M | -$31.1M | -$27.4M |
| Free cash flow | -$7.0M | -$12.2M | -$15.9M | -$31.3M | -$27.6M |
| Total assets | $5.5M | $5.5M | $6.3M | $17.4M | $41.1M |
| Total liabilities | $12.4M | $8.1M | $8.6M | $10.4M | $10.9M |
| Stockholders' equity | -$6.9M | -$2.6M | -$2.4M | $7.0M | $30.2M |
| Cash and investments | $1.8M | $1.8M | $2.6M | $13.3M | $37.2M |
| Total debt | $3.0M | $3.5M | $2.9M | $3.8M | $4.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 15, 2026 | Jul 6, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 7, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 22, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jun 9, 2026 | Jun 5, 2026 |
All 1000 Aspira Women’s Health Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.